About 30 results found for searched term "RS 09" (0.092 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M11423 | RS 09 | TLR |
| RS09 is a LPS peptide mimicry, which is a new class of TLR4 agonist adjuvant. RS09 can increase antibody production in a vaccine environment. | ||
| M2071 | ONX-0914 | Proteasome |
| PR-957 | ||
| Onx-0914 (PR-957) is a selective inhibitor of low molecular weight polypeptide 7 (LMP7), a chymotrypsin subunit of the immune proteasome. Onx-0914 blocks cytokine production and reduces the progression of experimental arthritis. Onx-0914 is a non-competitive irreversible inhibitor of mycobacterium proteasome (Ki=5.2 μM). Onx-0914 activates latent HIV-1 through HF-1-mediated p-TEFb activation. | ||
| M2238 | Dorsomorphin dihydrochloride | AMPK |
| BML-275 2HCl; Compound C 2HCl | ||
| Dorsomorphin (BML-275; Compound C) dihydrochloride is a potent inhibitor of AMP-activated protein kinase (AMPK), with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride induces autophagy. | ||
| M3634 | TAPI-1 | Immunology/Inflammation |
| TAPI-1 is an ADAM17/TACE inhibitor that blocks shedding of cytokine receptors with IC50 value of 8.09 microM. | ||
| M3946 | BML-275 | AMPK |
| Dorsomorphin, Compound C | ||
| BML-275 (Dorsomorphin) is a cell-permeable pyrazolopyrimidine compound shown to be an AMPK inhibitor with Ki of 109 nM in cell-free assays. | ||
| M11227 | FM-479 | JAK |
| Fm-479 was a negative control of FM-381 and showed no activity against JAK3 or other kinases. Fm-381 is a potent covalent reversible inhibitor of JAK3 targeting unique Cys909. For JAK3, FM-381 was 410, 2700 and 3600 times more selective than JAK1, JAK2 and TYK2 with IC50 of 127 pM. | ||
| M5127 | FIIN-2 | EGFR/HER2 |
| FIIN-2 is an irreversible, pan-FGFR inhibitor with IC50 of 3.09 nM, 4.3 nM, 27 nM and 45.3 nM for FGFR1/2/3/4, respectively. | ||
| M8367 | Ro 25-6981 maleate salt | GluR |
| Ro-25-6981 Maleate | ||
| Ro 25-6981 maleate salt is a potent and selective antagonist of NMDA glutamate receptors containing the NR2B subunit with IC50 values of .009 μM for NR2B vs. 52 μM for NR2A subunits. Ro 25-6981 has been shown to have neuroprotectant effects and to reduce inflammatory and neuropathic pain in rodent models. | ||
| M8408 | CU-CPT22 | TLR |
| CU-CPT22 is the first probe for the complex between toll-like receptors TLR1 and TLR2. CU-CPT22 shows dose-dependent inhibitory effects blocking Pam3CSK4-induced TLR1/2 activation with an IC50 of 0.58 ± 0.09 µM. | ||
| M8963 | JNJ-42041935 | HIF |
| JNJ42041935; HIF-PHD Inhibitor II | ||
| JNJ-42041935 is a potent, competitive, reversible, and selective inhibitor of PHD with pKi values of 7.91±0.04, 7.29 ±0.05, and 7.65±0.09 for PHD1, PHD2, and PHD3, respectively. | ||
| M9510 | JWG-071 | ERK |
| JWG-071 is the first reported kinase-selective chemical probe for ERK5, inhibits ERK5 and LRRK2 with IC50 of 88 and 109 nM, respectively. | ||
| M10698 | FM-381 | JAK |
| FM-381 is a potent, covalent, reversible JAK3 inhibitor that targets the Cys909 site. FM-381 for JAK3 IC50 The value is 127 pM, which is 410, 2700, and 3600 times more selective than JAK1, JAK2, and TYK2, respectively. | ||
| M11420 | MYCi975 | c-Myc |
| NUCC-0200975 | ||
| MYCi975 (Nuc-0200975) is an orally active MYC inhibitor that disrupts MYC/MAX interactions, promotes MYC T58 phosphorylation and MYC degradation, and impairs myC-driven gene expression. MYCi975 (NUC-0200975) has strong anti-tumor effect and good tolerance, increasing tumor immune cell infiltration and enhancing tumor sensitivity against PD1 immune studies. | ||
| M19097 | Scopolamine | 5-HT Receptor |
| Hyoscine; Scopine tropat | ||
| Scopolamine is a high affinity (nM) muscarinic antagonist. Scopolamine reversibly inhibited 5-HT3 receptor-responses with an IC50 of 2.09 μM. | ||
| M21148 | (R)-CR8 trihydrochloride | CDK |
| CR8, (R)-Isomer trihydrochloride | ||
| (R)-CR8 trihydrochloride, one of the isomers of CR8, is a potent CDK1/2/5/7/9 inhibitor with anti-proliferative and pro-apoptotic effects on CML cell lines. (R)-CR8 trihydrochloride inhibited CDK1/cyclin B (IC50=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM ), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). | ||
| M21159 | SD-36 | PROTAC |
| SD-36 is a potent STAT3 PROTAC degradation agent (Kd=~50 nM) with a high selectivity compared to other STAT members. SD-36 is composed of the STAT3 inhibitor SI-109, a linker, and an analog of Cereblon ligand Lenalidomide for E3 ubiquitin ligase. | ||
| M21222 | BIIB091 | BTK |
| The reversible BTK kinase inhibitor BIIB091 is a highly selective phase I clinical candidate compound for multiple sclerosis. | ||
| M21686 | Recombinant Mouse BAFF (HEK293, N-mFc) | Cytokines and Growth Factors |
| TNF Ligand Superfamily Member 13B; B-cell-activating factor | ||
| Recombinant Mouse BAFF (TNFSF13B/TNFSF20) belongs to the tumor necrosis factor family. TNFSF13/APRIL binds to the same 2 receptors. Together, they form a 2 ligands -2 receptors pathway involved in the stimulation of B- and T-cell function and the regulation of humoral immunity. The target gene encoding Ala127-Leu309 is expressed with a mFc tag at the N-terminus. | ||
| M25150 | Sotrovimab | Anti-infection |
| VIR 7831 | ||
| Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease. | ||
| M27806 | LUF6096 | Adenosine Receptor |
| LUF6096, a potent allosteric enhancer of the adenosine A3 receptor, is able to allosterically enhance agonist binding. LUF6096 shows low orthosteric affinity for any of the adenosine receptors. LUF6096 shows protective effects in myocardial ischemia/reperfusion injury. | ||
| M27863 | DC07090 dihydrochloride | Anti-infection |
| DC07090 dihydrochloride is a low toxicity, potent, reversible and competitive non-peptidyl human enterovirus 71 3C protease inhibitor with an IC50 and a Ki value for 21.72 μM and 23.29 μM. DC07090 dihydrochloride could also inhibit coxsackievirus A16 (CVA16) replication with an EC50 value of 27.76 μM. | ||
| M28090 | PF-00956980 | JAK |
| PF-00956980 is a reversible pan-JAK inhibitor with IC50 values of 2.2, 23.1 and 59.9 μM for JAK1, JAK2 and JAK3, respectively. PF-00956980 can be used in the research of lung and skin inflammatory diseases. | ||
| M28109 | PF-3758309 hydrochloride | PAK |
| PF-03758309 hydrochloride | ||
| PF-3758309 (PF-03758309) hydrochloride is a potent, orally available, and reversible ATP-competitive inhibitor of PAK4 (Kd= 2.7 nM; Ki=18.7 nM). PF-3758309 hydrochloride has the expected cellular functions of a PAK4 inhibitor: inhibition of anchorage-independent growth, induction of apoptosis, cytoskeletal remodeling, and inhibition of proliferation. | ||
| M28421 | (S)-UFR2709 | AChR/AChE |
| (S)-UFR2709 is a competitive nAChR antagonist and displays higher affinity for α4β2 nAChRs than for α7 nAChRs. (S)-UFR2709 decreases anxiety and reduces ethanol consumption and ethanol preference in alcohol-preferring rats. (S)-UFR2709 acts as an anxiolytic agent and can be used for the study of nicotine addiction. | ||
| M28650 | BRD0209 | GSK-3 |
| BRD0209 is a potent, selective and dual inhibitor of GSK3α/β inhibitor (GSK3α IC50 = 19 nM; GSK3β IC50 = 5 nM). BRD0209 is also a reversible ATP-competitive inhibitor with fast-off kinetics (Ki = 4.2 nM, respectively). BRD0209 is a tricyclic pyrazolotetrahydroquinolinone compound. BRD0209 has the potential for the research of mood disorder diseases. | ||
| M28807 | SHU 9119 acetate | Melanocortin Receptor |
| SHU 9119 acetate is a potent human melanocortin 3 and 4 receptors (MC3/4R) antagonist and a partial MC5R agonist; with IC50 values of 0.23, 0.06, and 0.09 nM for human MC3R, MC4R and MC5R, respectively. | ||
| M29006 | PC786 | RSV |
| PC786 is an inhaled respiratory syncytial virus (RSV) L protein polymerase inhibitor. PC786 demonstrates potent antiviral activity against RSV-A (IC50 <0.09 to 0.71 nM) and RSV-B (IC50, 1.3 to 50.6 nM). | ||
| M29348 | Multitarget AD inhibitor-1 | Gamma-secretase/Beta-secretase |
| Multitarget AD inhibitor-1 is a selective and reversible butyrylcholinesterase (BuChE) inhibitor with IC50s of 7.22 μM and 1.55 μM for hBuChE and eqBuChE (BuChE from equine serum), respectively. Multitarget AD inhibitor-1 inhibits β-secretase (IC50hBACE-1=41.60 μM), amyloid β aggregation (IC50Aβ=3.09 μM), tau aggregation. | ||
| M30160 | Anagyrine | AChR/AChE |
| (-)-Anagyrine; Monolupine; Rhombinine | ||
| Anagyrine ((-)-Anagyrine) is a quinolizidine alkaloid that has been found in Lupinus albus. Anagyrine binds to muscarinic and nicotinic acetylcholine receptors with IC50 values of 132 and 2096 µM respectively. Anagyrine is a potent and effective desensitizer of nAChR, and Anagyrine can directly, without metabolism, desensitize nAChR. | ||
| M30563 | Anagyrine hydrochloride | AChR/AChE |
| (-)-Anagyrine hydrochloride; Monolupine hydrochloride; Rhombinine hydrochloride | ||
| Anagyrine ((-)-Anagyrine) hydrochloride is a quinolizidine alkaloid that has been found in Lupinus albus. Anagyrine hydrochloride binds to muscarinic and nicotinic acetylcholine receptors with IC50 values of 132 and 2096 µM respectively. Anagyrine hydrochloride is a potent and effective desensitizer of nAChR, and Anagyrine hydrochloride can directly, without metabolism, desensitize nAChR. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
